Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aerosolized antibiotics are a common treatment option for patients with cystic fibrosis and chronic airway infection, as high doses can be delivered topically to the site of the infection while systemic exposure is minimized. Patients also use other aerosolized therapies (e.g. mucus-active agents, airway-wetting agents, and bronchodilators), adding significantly increase timed and complexity to their daily regimen, and often leading to lower adherence rates. A number of novel technological strategies are available that may reduce dose frequency and increase the speed of drug delivery. Psychologically based therapies may also be used to help modify behavior and thus improve adherence to treatment. Clinicians need to explore both technological and psychological strategies that will assist in the successful maintenance of treatment requirements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Barriers to Treatment Adherence for Children with Cystic Fibrosis and Asthma: What Gets in the Way?
Modi, A. C., & Quittner, A. L. (2006) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsj096 · Cited by 301
Accurate Assessment of Adherence
Daniels, T., Goodacre, L., Sutton, C., Pollard, K., Conway, S., & Peckham, D. (2011) · Chest · doi:10.1378/chest.09-3074 · Cited by 210
Adherence with tobramycin inhaled solution and health care utilization
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-5 · Cited by 95
Dziuban, E. J., Saab‐Abazeed, L., Chaudhry, S. R., Streetman, D. S., & Nasr, S. Z. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21195 · Cited by 88
McNamara, P. S., McCormack, P., McDonald, A. J., Heaf, L., & Southern, K. W. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.006 · Cited by 72
Research works printed but not linked: 60
- Gibson, 2003, Pathophysiology and management of pulmonary infections in cystic fibrosis, Am J Respir Crit Care Med, 168, 918, 10.1164/rccm.200304-505SO · DOI · Paper page
- Lipuma, 2010, The changing microbial epidemiology in cystic fibrosis, Clin Microbiol Rev, 23, 299, 10.1128/CMR.00068-09 · DOI · Paper page
- Hauser, 2011, Clinical significance of microbial infection and adaptation in cystic fibrosis, Clin Microbiol Rev, 24, 29, 10.1128/CMR.00036-10 · DOI · Paper page
- Flume, 2007, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med, 176, 957, 10.1164/rccm.200705-664OC · DOI · Paper page
- Heijerman, 2009, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus, J Cyst Fibros, 8, 295, 10.1016/j.jcf.2009.04.005 · DOI · Paper page
- Moskowitz, 2008, Shifting patterns of inhaled antibiotic use in cystic fibrosis, Pediatr Pulmonol, 43, 874, 10.1002/ppul.20873 · DOI
- Geller, 2009, Aerosol antibiotics in cystic fibrosis, Respir Care, 54, 658, 10.4187/aarc0537 · DOI · Paper page
- Arias Llorente, 2008, Treatment compliance in children and adults with cystic fibrosis, J Cyst Fibros, 7, 359, 10.1016/j.jcf.2008.01.003 · DOI · Paper page
- Czajkowski, 1987, Medical compliance and coping with cystic fibrosis, J Child Psychol Psychiatry, 28, 311, 10.1111/j.1469-7610.1987.tb00213.x · DOI
- Kettler, 2002, Determinants of adherence in adults with CF, Thorax, 57, 459, 10.1136/thorax.57.5.459 · DOI · Paper page
- Eakin, 2011, Longitudinal association between medication adherence and lung health in people with cystic fibrosis, J Cyst Fibros, 10, 258, 10.1016/j.jcf.2011.03.005 · DOI · Paper page
- Rau, 2005, Determinants of patient adherence to an aerosol regimen, Respir Care, 50, 1346
- Milgrom, 1996, Noncompliance and treatment failure in children with asthma, J Allergy Clin Immunol, 98, 1051, 10.1016/S0091-6749(96)80190-4 · DOI · Paper page
- Kesser, 2009, New aerosol delivery devices for cystic fibrosis, Respir Care, 54, 754, 10.4187/002013209790983250 · DOI
- Geller, 2008, The science of aerosol delivery in cystic fibrosis, Pediatr Pulmonol, 43, S5, 10.1002/ppul.20860 · doi:10.1002/ppul.20860
- Mendelman, 1985, Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum, Am Rev Respir Dis, 132, 761
- King, 2010, In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis, Antimicrob Agents Chemother, 54, 143, 10.1128/AAC.00248-09 · DOI
- Ramsey, 1993, Efficacy of aerosolized tobramycin in patients with cystic fibrosis, N Engl J Med, 328, 1740, 10.1056/NEJM199306173282403 · DOI · Paper page
- Chuchalin, 2007, A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study, Paediatr Drugs, 9, 21, 10.2165/00148581-200709001-00004 · DOI
- Coates, 2008, Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis, Pediatr Pulmonol, 4, 753, 10.1002/ppul.20850 · DOI
- Dupont, 2008, A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection, J Cyst Fibros, 7, S26, 10.1016/S1569-1993(08)60099-5 · DOI
- Okusanya, 2009, Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection, Antimicrob Agents Chemother, 53, 3847, 10.1128/AAC.00872-08 · DOI
- Bruinenberg, 2008, The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization, Pediatr Pulmonol, 43, 344
- Westerman, 2007, Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study, J Cyst Fibros, 6, 284, 10.1016/j.jcf.2006.10.010 · DOI
- Geller, 2011, Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology, J Aerosol Med Pulm Drug Deliv, 24, 175, 10.1089/jamp.2010.0855 · DOI · Paper page
- Newhouse, 2003, Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers, Chest, 124, 360, 10.1378/chest.124.1.360 · doi:10.1378/chest.124.1.360
- Geller, 2007, A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety, Pediatr Pulmonol, 42, 307, 10.1002/ppul.20594 · DOI · Paper page
- Konstan, 2011, Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial, Pediatr Pulmonol, 46, 230, 10.1002/ppul.21356 · DOI · Paper page
- Konstan, 2011, Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial, J Cyst Fibros, 10, 54, 10.1016/j.jcf.2010.10.003 · DOI · Paper page
- Stass, 2008, Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder, J Cyst Fibros, 7, S26, 10.1016/S1569-1993(08)60100-9 · doi:10.1016/s1569-1993(08)60100-9
- Tiddens, 2006, Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older, J Aerosol Med, 19, 456, 10.1089/jam.2006.19.456 · doi:10.1089/jam.2006.19.456
- Trapnell, 2011, Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection, Am J Respir Crit Care Med
- Yang, 2010, Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis, Pharm Res, 27, 151, 10.1007/s11095-009-9991-2 · DOI
- Gibson, 2006, Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis, Pediatr Pulmonol, 41, 656, 10.1002/ppul.20429 · DOI
- Geller, 2011, Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa, Am J Respir Crit Care Med, 183, 1510, 10.1164/rccm.201008-1293OC · DOI
- Hubert, 2009, Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis, J Cyst Fibros, 8, 332, 10.1016/j.jcf.2009.07.001 · doi:10.1016/j.jcf.2009.07.001
- Lenney, 2011, Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects, J Cyst Fibros, 10, 9, 10.1016/j.jcf.2010.08.019 · doi:10.1016/j.jcf.2010.08.019
- Denyer, 2010, The Adaptive Aerosol Delivery (AAD) technology: past, present, and future, J Aerosol Med Pulm Drug Deliv, 23, S1, 10.1089/jamp.2009.0791 · DOI
- Brand, 2000, Total deposition of therapeutic particles during spontaneous and controlled inhalations, J Pharm Sci, 89, 724, 10.1002/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO;2-B · doi:10.1002/(sici)1520-6017(200006)89:6<724::aid-jps3>3.0.co;2-b
- McCormack, 2011, A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis, J Cyst Fibros, 10, 343, 10.1016/j.jcf.2011.04.006 · DOI
- Bennett, 2005, Controlled inhalation of aerosolized therapeutics, Expert Opin Drug Deliv, 2, 763, 10.1517/17425247.2.4.763 · DOI
- Denyer, 2010, Adherence monitoring in drug delivery, Expert Opin Drug Deliv, 7, 1127, 10.1517/17425247.2010.517520 · DOI
- Gibson, 1988, Perspective in parental coping with a chronically ill child: the case of cystic fibrosis, Issues Compr Pediatr Nurs, 11, 33, 10.3109/01460868809026829 · doi:10.3109/01460868809026829
- Madge, 2006, 'Challenges for nurses', vol. 34, 286
- Burker, 2004, Psychological and educational factors: better predictors of work status than FEV1 in adults with CF, Pediatr Pulmonol, 38, 413, 10.1002/ppul.20090 · DOI · Paper page
- Moise, 1987, Correlates of psychosocial adjustment among young adults with cystic fibrosis, J Dev Behav Pediatr, 8, 141, 10.1097/00004703-198706000-00003 · DOI
- Oxley, 2005, How a clinical psychologist manages the problems of adults with cystic fibrosis, J R Soc Med, 98, 37
- Hafetz, 2010, Child and parent perceptions of monitoring in chronic illness management: a qualitative study, Child Care Health Dev, 36, 655, 10.1111/j.1365-2214.2010.01102.x · DOI
- Lehane, 2007, Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper, Int J Nurs Stud, 44, 1468, 10.1016/j.ijnurstu.2006.07.010 · DOI · Paper page
- Abbott, 1995, Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician, Thorax, 50, 794, 10.1136/thx.50.7.794 · DOI
- Duff, 2010, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it, J Cyst Fibros, 9, 455, 10.1016/j.jcf.2010.08.012 · DOI
- Bender, 2003, Adherence intervention research: what have we learned and what do we do next?, J Allergy Clin Immunol, 112, 489, 10.1016/S0091-6749(03)01718-4 · DOI
- Bender, 2000, Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT, Ann Allergy Asthma Immunol, 85, 416, 10.1016/S1081-1206(10)62557-4 · DOI · Paper page
- Elliott, 2005, Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence, Ann Pharmacother, 39, 508, 10.1345/aph.1E398 · DOI · Paper page
- McClimans, 2011, Health policy, patient-centred care and clinical ethics, J Eval Clin Pract, 17, 913, 10.1111/j.1365-2753.2011.01726.x · DOI
- Duff, 2010, Motivational interviewing for adherence problems in cystic fibrosis: state of the art review, Pediatr Pulmonol, 45, 211, 10.1002/ppul.21103 · DOI · Paper page
- Hides, 2011, Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse?, Med J Aust, 195, S31, 10.5694/j.1326-5377.2011.tb03263.x · DOI · Paper page
- Fowler, 2011, Adherence and competence assessment in studies of CBT for psychosis: current status and future directions, Epidemiol Psychiatr Sci, 20, 121, 10.1017/S2045796011000199 · DOI
- Brocklehurst, 2010, Personal construct psychology: a theory to help understand professional development, a philosophy to support it, Prim Dent Care, 17, 179, 10.1308/135576110792936140 · doi:10.1308/135576110792936140
- Melnyk, 2001, Coping in parents of children who are chronically ill: strategies for assessment and intervention, Pediatr Nurs, 27, 547
Cited by
European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre
Conway, S., Balfour-Lynn, I. M., De Rijcke, K., Drevinek, P., Foweraker, J., Havermans, T., Heijerman, H., Lannefors, L., Lindblad, A., Macek, M., et al. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.03.009 · Cited by 232
Self-citationDigital technologies and adherence in respiratory diseases: the road ahead
Blakey, J. D., Bender, B. G., Dima, A. L., Weinman, J., Safioti, G., & Costello, R. W. (2018) · European Respiratory Journal · doi:10.1183/13993003.01147-2018 · Cited by 136
Hoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s105530 · Cited by 27
“15,16 These data logging nebulizers provide rich data that can potentially be used to support adherence 15 with meta-analysis suggesting that feeding back data to patients can increase adherence by around 20%.”
Hoo, Z. H., Boote, J., Wildman, M. J., Campbell, M. J., & Gardner, B. (2017) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2017.1338958 · Cited by 21
Airway clearance and exercise for people with cystic fibrosis: balancing longevity with life
Rowbotham, N. J., & Daniels, T. E. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25734 · Cited by 16
Metadata
- Authors
- Geller, D. E., & Madge, S.
- Venue
- Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 105
- Pages
- S24-S31
- ISSN
- 0954-6111 (ISSN-L)
- OpenAlex
- W2027827270
- Cited by
- 39
- References
- 7
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 731 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. https://app.cochat.ai/papers/10.1016/s0954-6111(11)70024-5
- The paper
- Geller, D. E., & Madge, S. (2011). Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. Respiratory Medicine. https://doi.org/10.1016/s0954-6111(11)70024-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.